RMG Acquisition Corp. III (RMGCF) 10-Q 3 Jun 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Jun. 03, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2021
Entity File Number	001-40013
Entity Registrant Name	RMG ACQUISITION CORP. III
Entity Incorporation, State or Country Code	KY
Entity Tax Identification Number	98-1574120
Entity Address, Address Line One	57 Ocean, Suite 403
Entity Address, Address Line Two	5775 Collins Avenue
Entity Address, City or Town	Miami Beach
Entity Address State Or Province	FL
Entity Address, Postal Zip Code	33140
City Area Code	786
Local Phone Number	584-8352
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Central Index Key	0001838108
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant
Document Information [Line Items]
Title of 12(b) Security	Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant
Trading Symbol	RMGCU
Security Exchange Name	NASDAQ
Class A Common Stock
Document Information [Line Items]
Title of 12(b) Security	Class A ordinary shares included as part of the units
Trading Symbol	RMGC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		48,300,000
Redeemable Warrants Exercisable For Class Common Stock
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants included as part of the units
Trading Symbol	RMGCW
Security Exchange Name	NASDAQ
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		12,075,000

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 1,143,471
Prepaid expenses	1,057,758	$ 10,221
Total current assets	2,201,229	10,221
Deferred offering costs		25,000
Investments held in Trust Account	483,016,726
Total Assets	485,217,955	35,221
Current liabilities
Accounts payable	22,254
Accrued expenses	89,137	25,000
Total current liabilities	111,391	25,000
Deferred legal fees	250,000
Deferred underwriting commissions	16,905,000
Derivative warrant liabilities	25,026,860
Total Liabilities	42,293,251	25,000
Commitments and Contingencies
Shareholders' Equity:
Preference shares, $0.0001 par value 5,000,000 shares authorized none issued and outstanding
Additional paid-in capital	7,212,061	23,792
Accumulated deficit	(2,213,716)	(14,779)
Total shareholders' equity	5,000,004	10,221
Total Liabilities and Shareholders' Equity	485,217,955	35,221
Class A Common Stock
Shareholders' Equity:
Common stock	451
Total shareholders' equity	451
Class B Common Stock
Shareholders' Equity:
Common stock	1,208	1,208
Total shareholders' equity	$ 1,208	$ 1,208

CONDENSED BALANCE SHEET (Parent

CONDENSED BALANCE SHEET (Parenthetical)	Mar. 31, 2021$ / sharesshares
Preferred stock, par value, (per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Temporary equity, shares outstanding	43,792,470
Class A Common Stock
Common shares, par value, (per share) | $ / shares	$ 0.0001
Class A Common Stock Subject to Redemption
Temporary equity, shares outstanding	43,792,470
Purchase price, per unit | $ / shares	$ 10
Class A Common Stock Not Subject to Redemption
Common shares, par value, (per share) | $ / shares	$ 0.0001
Common shares, shares authorized	500,000,000
Common shares, shares issued	4,507,530
Common shares, shares outstanding	4,507,530
Class B Common Stock
Common shares, par value, (per share) | $ / shares	$ 0.0001
Common shares, shares authorized	50,000,000
Common shares, shares issued	12,075,000
Common shares, shares outstanding	12,075,000

UNAUDITED CONDENSED STATEMENT O

UNAUDITED CONDENSED STATEMENT OF OPERATIONS	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
UNAUDITED CONDENSED STATEMENT OF OPERATIONS
General and administrative expense	$ 259,412
Loss from operations	(259,412)
Other income (expense)
Change in fair value of derivative warrant liabilities	(1,221,950)
Financing costs - warrant liabilities	(734,320)
Interest income	19
Unrealized gain on investments held in Trust Account	16,726
Total other income (expense)	(717,575)
Net loss	$ (2,198,937)
Weighted average shares outstanding of common stock subject to redemption, basic and | shares	43,935,042
Weighted average shares outstanding of common stock, basic and diluted | shares	13,865,976
Basic and diluted net loss per share, common stock | $ / shares	$ (0.16)

UNAUDITED CONDENSED STATEMENT_2

UNAUDITED CONDENSED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - 3 months ended Mar. 31, 2021 - USD ($)	Class A Common Stock	Class B Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2020		$ 1,208	$ 23,792	$ (14,779)	$ 10,221
Balance at the beginning (in shares) at Dec. 31, 2020		12,075,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of units in initial public offering, less allocation of proceeds to Public Warrants	$ 4,830		470,131,490		470,136,320
Sale of units in initial public offering, less allocation of proceeds to Public Warrants (in shares)	48,300,000
Offering costs			(26,406,165)		(26,406,165)
Excess purchase price above fair value of private			1,383,265		1,383,265
Shares subject to possible redemption	$ (4,379)		(437,920,321)		(437,924,700)
Shares subject to possible redemption (in shares)	(43,792,470)
Net loss		$ 2,900,000		(2,198,937)	(2,198,937)
Balance at the end at Mar. 31, 2021	$ 451	$ 1,208	$ 7,212,061	$ (2,213,716)	$ 5,000,004
Balance at the end (in shares) at Mar. 31, 2021	4,507,530	12,075,000

UNAUDITED CONDENSED STATEMENT_3

UNAUDITED CONDENSED STATEMENT OF CASH FLOWS	3 Months Ended
	Mar. 31, 2021USD ($)
Cash Flows from Operating Activities:
Net loss	$ (2,198,937)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative warrant liabilities	1,221,950
Financing Costs Warrant Liabilities	734,320
Unrealized gain on investments held in Trust Account	(16,726)
Changes in operating assets and liabilities:
Prepaid expenses	(1,047,537)
Accounts payable	(62,086)
Accrued expenses	3,687
Net cash used in operating activities	(1,365,329)
Cash Flows from Investing Activities:
Cash deposited in Trust Account	(483,000,000)
Net cash used in investing activities	(483,000,000)
Cash Flows from Financing Activities:
Proceeds from note payable to related party	30,212
Repayment of note payable to related party	(135,000)
Proceeds received from initial public offering, gross	483,000,000
Proceeds received from issuance of warrants	12,324,495
Offering costs paid	(9,710,907)
Net cash provided by financing activities	485,508,800
Net Change in Cash	1,143,471
Cash - beginning of the period	0
Cash - Ending	1,143,471
Supplemental disclosure of noncash investing and financing activities:
Offering costs included in accounts payable	84,340
Offering costs included in accrued expenses	85,450
Offering costs paid by related party under promissory note	104,788
Reversal of accrued expenses	25,000
Deferred legal fees	250,000
Deferred underwriting Commission	16,905,000
Value of Class A ordinary shares subject to possible redemption	439,378,930
Change in value of Class A ordinary shares subject to possible redemption	$ (1,454,230)

Description of Organization and

Description of Organization and Business Operations	3 Months Ended
	Mar. 31, 2021
Description of Organization and Business Operations
Description of Organization and Business Operations	Note 1 — RMG Acquisition Corp. III (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on December 23, 2020. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”). As of March 31, 2021, the Company had not yet commenced operations. All activity for the period from December 23, 2020 (inception) through March 31, 2021 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is RMG Sponsor III, LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on February 4, 2021. On February 9, 2021, the Company consummated its Initial Public Offering of 48,300,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), including 6,300,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $483.0 million, and incurring offering costs of approximately $27.1 million, of which approximately $16.9 million was for deferred underwriting commissions and $250,000 was for deferred legal fees (Note 6). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 8,216,330 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $12.3 million (Note 4). Upon the closing of the Initial Public Offering and the Private Placement, $483.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and have been invested in United States government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act 1940, as amended, or the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide its holders of Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations, expenses relating to the administration of the trust account and limited withdrawals for working capital). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). These Public Shares will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which will be adopted by the Company upon the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares prior to this Initial Public Offering (the “Initial Shareholders”) agreed to vote their Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination. In addition, the Company agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association will provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, executive officers and directors agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment. If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or February 9, 2023, (the “Combination Period”), the Company will (1) cease all operations except for the purpose of winding up; (2) as promptly as reasonably possible but not more than 10 The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, expenses relating to the administration of the trust account and limited withdrawals for working capital, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources As of March 31, 2021, the Company had approximately $1.1 million in its operating bank account, and working capital of approximately $2.1 million. The Company’s liquidity needs to date have been satisfied through a payment of $25,000 from Sponsor to cover for certain expenses in exchange for the issuance of the Founder Shares (as defined in Note 5), the loan of $135,000 from the Sponsor pursuant to the Note (as defined in Note 5), and the proceeds from the consummation of the Private Placement not held in the Trust Account. The Company fully repaid the Note on February 12, 2021. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 5). As of March 31, 2021, there were no amounts outstanding under any Working Capital Loan. Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the period for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected through December 31, 2021. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Current Report on Form 8-K and the final prospectus filed by the Company with the SEC on February 16, 2021 and February 8, 2021, respectively. In April 2021, the Company identified a misstatement in its accounting treatment for warrants and a forward purchase agreement issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants (collectively, the “Warrants”) as presented in its audited balance sheet as of February 9, 2021 included in its Current Report on Form 8-K, filed February 16, 2021. The Warrants and the forward purchase agreement were reflected as a component of equity as opposed to liabilities on the balance sheet. Pursuant to FASB ASC Topic 250, Accounting Changes and Error Corrections February Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of March 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of March 31, 2021. Investments Held in Trust Account The Company’s portfolio of investments is comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in net gain on investments, dividends and interest held in Trust Account in the accompanying unaudited condensed statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements,” approximates the carrying amounts represented in the balance sheet. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of March 31, 2021, the carrying values of cash, accounts payable and accrued expenses approximate their fair values due to the short-term nature of the instruments. The Company’s marketable securities held in Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less and are recognized at fair value. The fair value of marketable securities held in Trust Account is determined using quoted prices in active markets. Derivative warrant liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued share purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued an aggregate of 9,660,000 Public Warrants (as defined below) as part of the Units issued to investors in our Initial Public Offering and the underwriters’ exercise of their overallotment option and we issued 8,216,330 Private Placement Warrants. All of our outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of warrants issued in connection with the Initial Public Offering and Private Placement were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement warrants have been estimated using a Monte Carlo simulation model each measurement date. The fair value of Warrants issued in connection with our Initial Public Offering have subsequently been measured based on the listed market price of such warrants. Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Class A ordinary shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at March 31, 2021, 43,792,470 Class A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet. ​ Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Net loss per ordinary shares Net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the periods. The Company has not considered the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the Over-allotment) and the private placement warrants to purchase an aggregate of 43,792,470 Class A ordinary shares in the calculation of diluted income per share, because their inclusion would be anti-dilutive under the treasury stock method. The Company’s unaudited condensed statements of operations include a presentation of loss per share for ordinary shares subject to redemption in a manner similar to the two-class method of income per share. Net loss per share, basic and diluted for Class A ordinary shares for three months ended March 31, 2021 is calculated by dividing the income on marketable securities, dividends and interest held in Trust Account of approximately $17,000, by the weighted average number of Class A ordinary shares outstanding for the periods. Net loss per share, basic and diluted for Class B ordinary shares for the three months ended March 31, 2021 is calculated by dividing the net loss of approximately $2.9 million, less net income attributable to Class A ordinary shares of approximately $17,000, resulting in a net loss of approximately $2.9 million, by the weighted average number of Class B ordinary shares outstanding for the periods. Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

Initial Public Offering

Initial Public Offering	3 Months Ended
	Mar. 31, 2021
Initial Public Offering
Initial Public Offering	Note 3— Initial Public Offering On February 9, 2021, the Company consummated its Initial Public Offering of 48,300,000 Units, including 6,300,000 Over-Allotment Units, at $10.00 per Unit, generating gross proceeds of $483.0 million, and incurring offering costs of approximately $27.1 million, of which approximately $16.9 million was for deferred underwriting commissions and $250,000 was for deferred legal fees. Each Unit consists of one Class A ordinary share and one

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions
Related Party Transactions	Note 4 — Related Party Transactions Founder Shares In December 2020, the Sponsor paid an aggregate of $25,000 to cover for certain expenses on behalf of the Company in exchange for issuance of 10,062,500 ordinary shares (the “Founder Shares”). On January 30, 2021, the Company effectuated a 5-for- 6 The Initial Shareholders agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (1) one year after the completion of the initial Business Combination; and (2) subsequent to the initial Business Combination (x) if the last reported sale price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination or (y) the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. Private Placement Warrants Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 8,216,330 Private Placement Warrants at a price of $1.50 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $12.3 million. Each whole Private Placement Warrant is exercisable for one whole share of Class A ordinary shares at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable for cash and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination. Related Party Loans On December 30, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note was non-interest bearing, unsecured and due upon the closing of the Initial Public Offering. As of February 9, 2021, the Company borrowed $135,000 under the Note. The Company repaid the Note balance in full on February 12, 2021. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, members of the Company’s founding team or any of their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lenders’ discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of March 31, 2021, the Company had no borrowings under the Working Capital Loans. Administrative Services Agreement Commencing on the effective date of the Registration Statement, the Company agreed to pay an affiliate of the Sponsor a total of $20,000 per month for office space, administrative and support services (including salaries). Upon the Company’s liquidation, the Company will cease paying these monthly fees. Upon completion of the Initial Business Combination, the Company will pay to such affiliate an amount equal to $20,000 multiplied by the number of whole months remaining between the date of the completion of the Initial Business Combination and the date that is 24 months from the closing of the Offering. The Company incurred approximately $40,000 in expenses in connection with such services during the three months ended March 31, 2021 as reflected in the accompanying statement of operations and had nil included in accrued expenses—related party in connection with such services. The Sponsor, officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. The audit committee will review on a quarterly basis all payments that were made by us to the Sponsor, directors, officers or the Company’s or any of their respective affiliates.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies.
Commitments and Contingencies	Note 5 — Commitments and Contingencies Registration and Shareholder Rights Agreement The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) were entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective date of the Initial Public Offering. The holders of these securities were entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45 -day ​ The underwriters were entitled to an underwriting discount of $0.20 per unit, or approximately $9.7 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or approximately $16.9 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statement. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2021
Shareholders' Equity
Shareholders' Equity	Note 6 — Shareholders’ Equity Preference Shares  —  no outstanding Class A Ordinary Shares  —  issued Class B Ordinary Shares  —  issued 6 Only holders of Class B ordinary shares will have the right to vote on the election of directors prior to the initial Business Combination. Holders of the Class A ordinary shares and holders of the Class B ordinary shares will vote together as a single class on all other matters submitted to a vote of the shareholders, except as required by law. Each ordinary share will have one vote on all such matters. The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of the initial Business Combination, the ratio at which the Class B ordinary shares will convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of all ordinary shares issued and outstanding upon the completion of the Initial Public Offering plus all Class A ordinary shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination, excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one to one.

Derivative Warrant Liabilities

Derivative Warrant Liabilities	3 Months Ended
	Mar. 31, 2021
Derivative Warrant Liabilities
Derivative Warrant Liabilities	Note 7 — Derivative Warrant Liabilities As of March 31, 2021, the Company had 9,660,000 and 8,216,330 Public Warrants and Private Placement Warrants, respectively, outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement). The Company agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, requires holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement. The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long as they are held by the initial purchasers or such purchasers’ permitted transferees. If the Private Placement Warrants are held by someone other than the Initial Shareholders or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. Redemption of warrants for cash when the price per Class A ordinary share equals or exceeds $18.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon not less than 30 days ' prior written notice of redemption to each warrant holder; and ● if, and only if, the last reported sale price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30- trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. The Company will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants: ● in whole and not in part; ● at $0.10 per warrant upon a minimum of 30 days ’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; ● if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per Public Share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and ● if the closing price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. ​ The “fair market value” of Class A ordinary shares shall mean the average reported last sale price of Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Measurements
Fair Value Measurements	Note 8 — Fair Value Measurements The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant Other Significant Other ​ ​ in ​ Observable ​ Unobservable ​ ​ Active Markets ​ Inputs ​ Inputs Description ​ (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ Investments held in Trust Account $ 483,016,726 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ Derivative warrant liabilities - public ​ $ 13,524,000 ​ $ — ​ $ — Derivative warrant liabilities - private $ — ​ $ — ​ $ 11,502,860 ​ Transfers to/from Levels 1 2 Level 1 instruments include investments in money market funds and U.S. Treasury securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement Warrants have been estimated using a Monte Carlo simulation model each measurement date. For the three months ended March 31, 2021, the Company recognized a charge to the statement of operations resulting from a decrease in the fair value of liabilities of approximately $1.2 million presented as change in fair value of derivative warrant liabilities on the accompanying statement of operations. ​ The estimated fair value of the Private Placement Warrants, and the Public Warrants prior to being separately listed and traded, is determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its Public Warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement dates: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 9, 2021 ​ As of March 31, 2021 ​ Share price $ 9.73 ​ $ 9.80 ​ Volatility ​ ​ 24.2 % 14.0 % Expected life of the options to convert ​ ​ 6.18 ​ 6.0 ​ Risk-free rate ​ ​ 0.65 % ​ 1.17 % Dividend yield ​ ​ — ​ — ​ ​ The change in the level 3 fair value of the derivative warrant liabilities for the period from January 13, 2021 (inception) through March 31, 2021 is summarized as follows: ​ ​ ​ ​ ​ Derivative warrant liabilities at January 13, 2021 (inception) ​ $ — Issuance of Public and Private Warrants ​ 23,804,910 Change in fair value of derivative warrant liabilities ​ ​ 1,221,950 Transfer of Public Warrants to Level 1 ​ ​ (13,524,000) Derivative warrant liabilities at March 31, 2021 ​ $ 11,502,860 ​

Revision to Prior Period Financ

Revision to Prior Period Financial Statements	3 Months Ended
	Mar. 31, 2021
Revision to Prior Period Financial Statements
Revision to Prior Period Financial Statements	Note 9—Revision to Prior Period Financial Statements During the course of preparing the quarterly report on Form 10-Q for the three months ended March 31, 2021, the Company identified a misstatement in its misapplication of accounting guidance related to the Company’s warrants in the Company’s previously issued audited balance sheet dated February 9, 2021, filed on Form 8-K on February 16, 2021 (the “Post-IPO Balance Sheet”). On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since their issuance on February 9, 2021, the Company’s warrants have been accounted for as equity within the Company’s previously reported balance sheets. After discussion and evaluation, including with the Company’s independent registered public accounting firm and the Company’s audit committee, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement. The Warrants were reflected as a component of equity in the Post-IPO Balance Sheet as opposed to liabilities on the balance sheet, based on the Company’s application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity The Company concluded that the misstatement was not material to the Post-IPO Balance Sheet and the misstatement had no material impact to any prior interim period. The effect of the revisions to the Post-IPO Balance Sheet is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of February 9, 2021 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ Reported Adjustments As Revised Unaudited Condensed Balance Sheet ​ ​ ​ Total assets ​ $ 486,762,576 ​ $ — ​ $ 486,762,576 Liabilities and stockholders’ equity ​ ​ ​ Total current liabilities ​ $ 1,423,727 ​ $ — ​ $ 1,423,727 Deferred legal fees ​ 250,000 ​ 250,000 ​ Deferred underwriting commissions ​ 16,905,000 ​ — ​ 16,905,000 Derivative warrant liabilities ​ — ​ 23,804,910 ​ 23,804,910 Total liabilities ​ 18,578,727 ​ 23,804,910 ​ 42,383,637 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption ​ 463,183,840 ​ (23,804,910) ​ 439,378,930 Shareholders’ equity ​ ​ ​ Preference shares- $0.0001 par value ​ — ​ — ​ — Class A ordinary shares - $0.0001 par value ​ 198 ​ 238 ​ 436 Class B ordinary shares - $0.0001 par value ​ 1,208 ​ — ​ 1,208 Additional paid-in-capital ​ 5,046,808 ​ 734,082 ​ 5,780,890 Accumulated deficit ​ (48,205) ​ (734,320) ​ (782,525) Total shareholders’ equity ​ 5,000,009 ​ — ​ 5,000,009 Total liabilities and shareholders’ equity ​ $ 486,762,576 ​ $ — ​ $ 486,762,576 ​

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events
Subsequent Events	Note 10 — Subsequent Events The Company evaluated subsequent events and transactions that occurred up to the date unaudited condensed financial statements were available to be issued. Based upon this review, the Company determined that, except as disclosed in Note 1, there have been no events that have occurred that would require adjustments to the disclosures in the unaudited condensed financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the period for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected through December 31, 2021. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Current Report on Form 8-K and the final prospectus filed by the Company with the SEC on February 16, 2021 and February 8, 2021, respectively. In April 2021, the Company identified a misstatement in its accounting treatment for warrants and a forward purchase agreement issued in connection with the Initial Public Offering (the “Public Warrants”) and the Private Placement Warrants (collectively, the “Warrants”) as presented in its audited balance sheet as of February 9, 2021 included in its Current Report on Form 8-K, filed February 16, 2021. The Warrants and the forward purchase agreement were reflected as a component of equity as opposed to liabilities on the balance sheet. Pursuant to FASB ASC Topic 250, Accounting Changes and Error Corrections February
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of March 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of March 31, 2021.
Investments Held in Trust Account	Investments Held in Trust Account The Company’s portfolio of investments is comprised solely of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in net gain on investments, dividends and interest held in Trust Account in the accompanying unaudited condensed statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Financial Instruments	Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements,” approximates the carrying amounts represented in the balance sheet.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of March 31, 2021, the carrying values of cash, accounts payable and accrued expenses approximate their fair values due to the short-term nature of the instruments. The Company’s marketable securities held in Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less and are recognized at fair value. The fair value of marketable securities held in Trust Account is determined using quoted prices in active markets.
Derivative warrant liabilities	Derivative warrant liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued share purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued an aggregate of 9,660,000 Public Warrants (as defined below) as part of the Units issued to investors in our Initial Public Offering and the underwriters’ exercise of their overallotment option and we issued 8,216,330 Private Placement Warrants. All of our outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of warrants issued in connection with the Initial Public Offering and Private Placement were initially measured at fair value using a Monte Carlo simulation model and subsequently, the fair value of the Private Placement warrants have been estimated using a Monte Carlo simulation model each measurement date. The fair value of Warrants issued in connection with our Initial Public Offering have subsequently been measured based on the listed market price of such warrants.
Offering Costs Associated with the Initial Public Offering	Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Class A ordinary shares were charged to shareholders’ equity upon the completion of the Initial Public Offering.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at March 31, 2021, 43,792,470 Class A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet.
Income Taxes	Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net loss per ordinary shares	Net loss per ordinary shares Net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the periods. The Company has not considered the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the Over-allotment) and the private placement warrants to purchase an aggregate of 43,792,470 Class A ordinary shares in the calculation of diluted income per share, because their inclusion would be anti-dilutive under the treasury stock method. The Company’s unaudited condensed statements of operations include a presentation of loss per share for ordinary shares subject to redemption in a manner similar to the two-class method of income per share. Net loss per share, basic and diluted for Class A ordinary shares for three months ended March 31, 2021 is calculated by dividing the income on marketable securities, dividends and interest held in Trust Account of approximately $17,000, by the weighted average number of Class A ordinary shares outstanding for the periods. Net loss per share, basic and diluted for Class B ordinary shares for the three months ended March 31, 2021 is calculated by dividing the net loss of approximately $2.9 million, less net income attributable to Class A ordinary shares of approximately $17,000, resulting in a net loss of approximately $2.9 million, by the weighted average number of Class B ordinary shares outstanding for the periods.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Measurements
Schedule of company's assets that are measured at fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices Significant Other Significant Other ​ ​ in ​ Observable ​ Unobservable ​ ​ Active Markets ​ Inputs ​ Inputs Description ​ (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ Investments held in Trust Account $ 483,016,726 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ Derivative warrant liabilities - public ​ $ 13,524,000 ​ $ — ​ $ — Derivative warrant liabilities - private $ — ​ $ — ​ $ 11,502,860
Schedule of quantitative information regarding Level 3 fair value measurements inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 9, 2021 ​ As of March 31, 2021 ​ Share price $ 9.73 ​ $ 9.80 ​ Volatility ​ ​ 24.2 % 14.0 % Expected life of the options to convert ​ ​ 6.18 ​ 6.0 ​ Risk-free rate ​ ​ 0.65 % ​ 1.17 % Dividend yield ​ ​ — ​ — ​
Schedule of change in the fair value of the warrant liabilities	​ ​ ​ ​ ​ Derivative warrant liabilities at January 13, 2021 (inception) ​ $ — Issuance of Public and Private Warrants ​ 23,804,910 Change in fair value of derivative warrant liabilities ​ ​ 1,221,950 Transfer of Public Warrants to Level 1 ​ ​ (13,524,000) Derivative warrant liabilities at March 31, 2021 ​ $ 11,502,860

Revision to Prior Period Fina_2

Revision to Prior Period Financial Statements (Tables)	3 Months Ended
	Mar. 31, 2021
Revision to Prior Period Financial Statements
Summary of effect of the revisions to the post-IPO balance sheet	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of February 9, 2021 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ Reported Adjustments As Revised Unaudited Condensed Balance Sheet ​ ​ ​ Total assets ​ $ 486,762,576 ​ $ — ​ $ 486,762,576 Liabilities and stockholders’ equity ​ ​ ​ Total current liabilities ​ $ 1,423,727 ​ $ — ​ $ 1,423,727 Deferred legal fees ​ 250,000 ​ 250,000 ​ Deferred underwriting commissions ​ 16,905,000 ​ — ​ 16,905,000 Derivative warrant liabilities ​ — ​ 23,804,910 ​ 23,804,910 Total liabilities ​ 18,578,727 ​ 23,804,910 ​ 42,383,637 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption ​ 463,183,840 ​ (23,804,910) ​ 439,378,930 Shareholders’ equity ​ ​ ​ Preference shares- $0.0001 par value ​ — ​ — ​ — Class A ordinary shares - $0.0001 par value ​ 198 ​ 238 ​ 436 Class B ordinary shares - $0.0001 par value ​ 1,208 ​ — ​ 1,208 Additional paid-in-capital ​ 5,046,808 ​ 734,082 ​ 5,780,890 Accumulated deficit ​ (48,205) ​ (734,320) ​ (782,525) Total shareholders’ equity ​ 5,000,009 ​ — ​ 5,000,009 Total liabilities and shareholders’ equity ​ $ 486,762,576 ​ $ — ​ $ 486,762,576

Description of Organization a_2

Description of Organization and Business Operations (Details)	Feb. 09, 2021USD ($)$ / sharesshares	Oct. 14, 2020	Mar. 31, 2021USD ($)$ / sharesshares
Subsidiary, Sale of Stock [Line Items]
Condition for future business combination number of businesses minimum		1
Proceeds from issuance initial public offering			$ 483,000,000
Deferred underwriting commission			250,000
Proceeds received from issuance of warrants			$ 12,324,495
Threshold minimum aggregate fair market value as a percentage of the net assets held in the Trust Account			80.00%
Threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination			50.00%
Minimum net tangible assets upon consummation of the Business Combination			$ 5,000,001
Threshold percentage of Public Shares subject to redemption without the Company's prior written consent			15.00%
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)			100.00%
Redemption period upon closure			10 days
Business combination closing months			24 months
Maximum net interest to pay dissolution expenses			$ 100,000
Cash operating bank account			1,143,471
Working capital			2,100,000
Aggregate purchase price			25,000
Loan from the Sponsor			30,212
Loans from working capital			0
Sponsor
Subsidiary, Sale of Stock [Line Items]
Loan from the Sponsor			$ 135,000
Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) | shares			8,216,330
Price of warrant | $ / shares			$ 1.50
Proceeds received from issuance of warrants			$ 12,300,000
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Sale of units in initial public offering, less allocation of proceeds to Public Warrants (in shares) | shares	48,300,000
Purchase price, per unit | $ / shares	$ 10
Proceeds from issuance initial public offering	$ 483,000,000
Offering Costs	27,100,000
Underwriting commission	16,900,000
Deferred underwriting commission	$ 250,000
Private Placement
Subsidiary, Sale of Stock [Line Items]
Sale of units in initial public offering, less allocation of proceeds to Public Warrants (in shares) | shares	483,000,000
Private Placement | Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares) | shares	8,216,330
Price of warrant | $ / shares	$ 1.50
Proceeds received from issuance of warrants	$ 12,300,000
Over-Allotment Units
Subsidiary, Sale of Stock [Line Items]
Sale of units in initial public offering, less allocation of proceeds to Public Warrants (in shares) | shares	6,300,000
Purchase price, per unit | $ / shares	$ 10

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Feb. 09, 2021	Jan. 30, 2021
Summary of Significant Accounting Policies [Line items]
Cash equivalents	$ 0
Derivative warrant liabilities	25,026,860
FDIC Insurance coverage amount	$ 250,000
Class A ordinary shares subject to possible redemption	43,792,470
Net loss	$ (2,198,937)
Unrecognized tax benefits	0
Unrecognized tax benefits accrued for interest and penalties	$ 0
Anti-dilutive securities attributable to warrants (in shares)	43,792,470
Public Warrant
Summary of Significant Accounting Policies [Line items]
Number of warrants issued	9,660,000
Private Placement Warrant
Summary of Significant Accounting Policies [Line items]
Number of warrants issued	8,216,330
Reclassification
Summary of Significant Accounting Policies [Line items]
Derivative warrant liabilities		$ 23,800,000
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption		$ (23,800,000)
Class A Common Stock
Summary of Significant Accounting Policies [Line items]
Net income on investment	$ 17,000
Class B Common Stock
Summary of Significant Accounting Policies [Line items]
Net loss	$ 2,900,000
Shares subject to forfeiture			1,575,000

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)	Feb. 09, 2021	Mar. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Proceeds received from initial public offering, gross		$ 483,000,000
Offering costs		9,710,907
Deferred underwriting commissions		16,905,000
Deferred legal fees		$ 250,000
Public Warrant
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants		$ 11.50
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of units issued	48,300,000
Purchase price, per unit	$ 10
Proceeds received from initial public offering, gross	$ 483,000,000
Offering costs	27,100,000
Deferred underwriting commissions	16,900,000	$ 16,900,000
Deferred legal fees	$ 250,000
Initial Public Offering | Public Warrant
Subsidiary, Sale of Stock [Line Items]
Number of shares in a unit	1
Number of warrants in a unit	0.2
Number of shares issuable per warrant	1
Exercise price of warrants	$ 11.50
Over-Allotment Units
Subsidiary, Sale of Stock [Line Items]
Number of units issued	6,300,000
Purchase price, per unit	$ 10

Related Party Transactions - Fo

Related Party Transactions - Founder Shares (Details)	Jan. 30, 2021shares	Dec. 31, 2020USD ($)shares	Mar. 31, 2021USD ($)D$ / sharesshares	Feb. 09, 2021shares
Related Party Transaction [Line Items]
Aggregate purchase price | $			$ 25,000
Class B Common Stock
Related Party Transaction [Line Items]
Stock split ratio	1.2
Common shares, shares outstanding (in shares)	12,075,000	12,075,000	12,075,000	10,062,500
Shares subject to forfeiture	1,575,000
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders			20.00%
Founder Shares | Sponsor | Class B Common Stock
Related Party Transaction [Line Items]
Aggregate purchase price | $		$ 25,000
Number of shares issued		10,062,500
Stock split ratio	1.2
Common shares, shares outstanding (in shares)	12,075,000
Shares subject to forfeiture	1,575,000
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders	20.00%
Shares no longer subject to forfeiture				1,575,000
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares			$ 12
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D			20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D			30
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences			150 days

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Feb. 09, 2021	Dec. 30, 2020
Related Party Transaction [Line Items]
Proceeds received from issuance of warrants	$ 12,324,495
Private Placement Warrants
Related Party Transaction [Line Items]
Number of warrants issued	8,216,330
Proceeds received from issuance of warrants	$ 12,300,000
Exercise price of warrants	$ 11.50
Period after completion of initial business combination	30 days
Price of warrant	$ 1.50
Administrative Services Agreement
Related Party Transaction [Line Items]
Expenses per month	$ 20,000
Period from the closing of The offering for calculating expenses	24 months
Expenses incurred and paid	$ 40,000
Related Party Loans
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note			$ 300,000
Amount borrowed		$ 135,000
Related Party Loans | Working capital loans warrant
Related Party Transaction [Line Items]
Loan conversion agreement warrant	$ 1,500,000
Price of warrant	$ 1.50

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Feb. 09, 2021	Mar. 31, 2021
Commitments & contingencies [Line Items]
Granted Term	45 days
Underwriting cash discount per unit		$ 0.20
Underwriter cash discount		$ 9,700,000
Deferred commission per unit		$ 0.35
Deferred underwriting commission		$ 250,000
Deferred underwriting commissions		16,905,000
Over-Allotment Units
Commitments & contingencies [Line Items]
Number of units issued	6,300,000
Initial Public Offering
Commitments & contingencies [Line Items]
Number of units issued	48,300,000
Deferred underwriting commission	$ 250,000
Deferred underwriting commissions	$ 16,900,000	$ 16,900,000

Shareholders' Equity - Preferre

Shareholders' Equity - Preferred Stock Shares (Details) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Shareholders' Equity
Preferred shares, shares authorized	5,000,000	5,000,000
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0

Shareholders' Equity - Common S

Shareholders' Equity - Common Stock Shares (Details)	Jan. 30, 2021shares	Mar. 31, 2021Vote$ / sharesshares	Feb. 09, 2021shares	Dec. 31, 2020$ / sharesshares
Class of Stock [Line Items]
Class A common stock subject to possible redemption, outstanding (in shares)		43,792,470
Class A Common Stock
Class of Stock [Line Items]
Common shares, par value (in dollars per share) | $ / shares		$ 0.0001
Class A Common Stock Subject to Redemption
Class of Stock [Line Items]
Class A common stock subject to possible redemption, outstanding (in shares)		43,792,470		0
Class A Common Stock Not Subject to Redemption
Class of Stock [Line Items]
Common shares, shares authorized (in shares)		500,000,000		500,000,000
Common shares, par value (in dollars per share) | $ / shares		$ 0.0001		$ 0.0001
Common shares, votes per share | Vote		1
Common shares, shares issued (in shares)		4,507,530		0
Common shares, shares outstanding (in shares)		4,507,530		0
Class B Common Stock
Class of Stock [Line Items]
Common shares, shares authorized (in shares)		50,000,000		50,000,000
Common shares, par value (in dollars per share) | $ / shares		$ 0.0001		$ 0.0001
Common shares, shares issued (in shares)		12,075,000	10,062,500	12,075,000
Common shares, shares outstanding (in shares)	12,075,000	12,075,000	10,062,500	12,075,000
Stock split ratio	1.2
Shares subject to forfeiture	1,575,000
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders		20.00%

Derivative Warrant Liabilities

Derivative Warrant Liabilities (Details)	Jan. 30, 2021shares	Mar. 31, 2021Ditem$ / sharesshares
Class B Common Stock
Class of Warrant or Right [Line Items]
Shares subject to forfeiture | shares	1,575,000
Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)	20.00%
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrant outstanding | shares		8,216,330
Exercise price of warrants		$ 11.50
Restrictions on transfer period of time after business combination completion		30 days
Public Warrant
Class of Warrant or Right [Line Items]
Warrant outstanding | shares		9,660,000
Warrant exercise period condition one		30 days
Warrant exercise period condition two		12 months
Public Warrants expiration term		5 years
Threshold period for filling registration statement after business combination | item		20
Maximum threshold period for registration statement to become effective after business combination | item		60
Exercise price of warrants		$ 11.50
Share price		$ 9.20
Threshold trading days for redemption of public warrants | item		20
Threshold consecutive trading days for redemption of public warrants | item		10
Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant		60
Public Warrant | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00
Class of Warrant or Right [Line Items]
Class of warrants exercise price adjustment percentage		115.00%
Warrant redemption condition minimum share price		$ 18
Redemption price per public warrant (in dollars per share)		$ 0.01
Threshold trading days for redemption of public warrants | D		20
Threshold consecutive trading days for redemption of public warrants | D		30
Redemption period		30 days
Share price trigger used to measure dilution of warrant		$ 18
Public Warrant | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00
Class of Warrant or Right [Line Items]
Class of warrants exercise price adjustment percentage		180.00%
Warrant redemption condition minimum share price		$ 10
Warrant redemption condition minimum share price scenario two		18
Redemption price per public warrant (in dollars per share)		$ 0.10
Threshold trading days for redemption of public warrants		20
Threshold consecutive trading days for redemption of public warrants		30
Redemption period		30 days
Share price trigger used to measure dilution of warrant		$ 10

Fair Value Measurements (Detail

Fair Value Measurements (Details)	3 Months Ended
	Mar. 31, 2021USD ($)
Liabilities, Fair Value Disclosure [Abstract]
Derivative warrant liabilities	$ 25,026,860
Fair value assets level 1 to level 2 transfers	0
Fair value assets level 2 to level 1 transfers	0
Fair value assets transferred into (out of) level 3	3
Level 1
Assets:
Investments held in Trust Account	483,016,726
Level 1 | Public Warrant
Liabilities, Fair Value Disclosure [Abstract]
Derivative warrant liabilities	13,524,000
Level 3 | Private Placement Warrants
Liabilities, Fair Value Disclosure [Abstract]
Derivative warrant liabilities	$ 11,502,860

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Fair Value Measurements Inputs (Details)	3 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Feb. 09, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of derivative warrant liabilities		$ 1,221,950
Decrease in fair value of liabilities		$ 1,200,000
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input	9.80	9.80	9.73
Change in fair value of derivative warrant liabilities	$ (13,524,000)
Volatility | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input	14	14	24.2
Expected life of the options to convert | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input	6	6	6.18
Risk-free rate | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input	1.17	1.17	0.65

Fair Value Measurements - Chang

Fair Value Measurements - Change in the Fair Value of the Warrant Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Transfer of Public Warrants to Level 1		$ 1,221,950
Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Issuance of Public and Private Warrants	$ 23,804,910
Change in fair value of warrant liabilities	1,221,950
Transfer of Public Warrants to Level 1	(13,524,000)
Derivative warrant liabilities at March 31, 2021	$ 11,502,860	$ 11,502,860

Revision to Prior Period Fina_3

Revision to Prior Period Financial Statements - Effect of the revisions to the post-IPO balance sheet (Details) - USD ($)	Mar. 31, 2021	Feb. 09, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Assets	$ 485,217,955		$ 35,221
Liabilities and stockholders' equity
Total current liabilities	111,391		25,000
Deferred legal fees	250,000
Deferred underwriting commissions	16,905,000
Derivative warrant liabilities	25,026,860
Total Liabilities	42,293,251		25,000
Shareholders' equity
Preference shares- $0.0001 par value
Additional paid-in-capital	7,212,061		23,792
Accumulated deficit	(2,213,716)		(14,779)
Total shareholders' equity	5,000,004		10,221
Total Liabilities and Shareholders' Equity	$ 485,217,955		$ 35,221
Class A ordinary shares subject to possible redemption, par value, (per share)	$ 0.0001
Preferred stock, par value, (per share)	$ 0.0001		$ 0.0001
Class A Common Stock
Shareholders' equity
Common stock	$ 451
Total shareholders' equity	$ 451
Common shares, par value, (per share)	$ 0.0001
Class A Common Stock Subject to Redemption
Liabilities and stockholders' equity
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	$ 437,924,700
Class B Common Stock
Shareholders' equity
Common stock	1,208		$ 1,208
Total shareholders' equity	$ 1,208		$ 1,208
Common shares, par value, (per share)	$ 0.0001		$ 0.0001
Initial Public Offering
Liabilities and stockholders' equity
Deferred legal fees		$ 250,000
Deferred underwriting commissions	$ 16,900,000	$ 16,900,000
Post-IPO
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Assets	486,762,576
Liabilities and stockholders' equity
Total current liabilities	1,423,727
Deferred underwriting commissions	16,905,000
Derivative warrant liabilities	23,804,910
Total Liabilities	42,383,637
Shareholders' equity
Additional paid-in-capital	5,780,890
Accumulated deficit	(782,525)
Total shareholders' equity	5,000,009
Total Liabilities and Shareholders' Equity	486,762,576
Post-IPO | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total Assets	486,762,576
Liabilities and stockholders' equity
Total current liabilities	1,423,727
Deferred legal fees	250,000
Deferred underwriting commissions	16,905,000
Total Liabilities	18,578,727
Shareholders' equity
Additional paid-in-capital	5,046,808
Accumulated deficit	(48,205)
Total shareholders' equity	5,000,009
Total Liabilities and Shareholders' Equity	486,762,576
Post-IPO | Adjustments
Liabilities and stockholders' equity
Deferred legal fees	250,000
Derivative warrant liabilities	23,804,910
Total Liabilities	23,804,910
Shareholders' equity
Additional paid-in-capital	734,082
Accumulated deficit	(734,320)
Post-IPO | Class A Common Stock
Shareholders' equity
Common stock	436
Post-IPO | Class A Common Stock | As Previously Reported
Shareholders' equity
Common stock	198
Post-IPO | Class A Common Stock | Adjustments
Shareholders' equity
Common stock	238
Post-IPO | Class A Common Stock Subject to Redemption
Liabilities and stockholders' equity
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	439,378,930
Post-IPO | Class A Common Stock Subject to Redemption | As Previously Reported
Liabilities and stockholders' equity
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	463,183,840
Post-IPO | Class A Common Stock Subject to Redemption | Adjustments
Liabilities and stockholders' equity
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption	(23,804,910)
Post-IPO | Class B Common Stock
Shareholders' equity
Common stock	1,208
Post-IPO | Class B Common Stock | As Previously Reported
Shareholders' equity
Common stock	$ 1,208